Our results suggested that the sensitivity of GC cells to several EGFR inhibitors, including erlotinib, gefitinib and lapatinib, is closely related to IGFBP7 expression and that knocking down IGFBP7 significantly increased erlotinib sensitivity in GC cells. This evidence concerns the gene EGFR and gastric cancer.